bluebird bio Inc
NASDAQ:BLUE
bluebird bio Inc
EPS (Diluted)
bluebird bio Inc
EPS (Diluted) Peer Comparison
Competitive EPS (Diluted) Analysis
Latest Figures & CAGR of Competitors
Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
bluebird bio Inc
NASDAQ:BLUE
|
EPS (Diluted)
$0
|
CAGR 3-Years
56%
|
CAGR 5-Years
39%
|
CAGR 10-Years
-13%
|
|
Abbvie Inc
NYSE:ABBV
|
EPS (Diluted)
$2
|
CAGR 3-Years
0%
|
CAGR 5-Years
-6%
|
CAGR 10-Years
1%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
EPS (Diluted)
$0
|
CAGR 3-Years
18%
|
CAGR 5-Years
-39%
|
CAGR 10-Years
-18%
|
|
Amgen Inc
NASDAQ:AMGN
|
EPS (Diluted)
$7
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
1%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
EPS (Diluted)
$13
|
CAGR 3-Years
11%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
EPS (Diluted)
$33
|
CAGR 3-Years
-3%
|
CAGR 5-Years
10%
|
CAGR 10-Years
25%
|
See Also
What is bluebird bio Inc's EPS (Diluted)?
EPS (Diluted)
-0.8
USD
Based on the financial report for Sep 30, 2023, bluebird bio Inc's EPS (Diluted) amounts to -0.8 USD.
What is bluebird bio Inc's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 10Y
-13%
Over the last year, the EPS (Diluted) growth was 87%. The average annual EPS (Diluted) growth rates for bluebird bio Inc have been 56% over the past three years , 39% over the past five years , and -13% over the past ten years .